In recent years, small extracellular vesicles (sEVs) derived from mesenchymal stem cells (MSCs) have emerged as an intriguing cell-free therapeutic platform. These vesicles, nanosized membrane-bound particles, carry bioactive molecules including proteins, lipids, and nucleic acids that can modulate recipient cell behavior. MSC-derived sEVs have demonstrated potential in various inflammatory conditions by exerting immunoregulatory functions and promoting tissue repair. However, the baseline therapeutic efficacy of unstimulated MSC-sEVs can be insufficient, particularly in environments characterized by high-grade inflammation such as the degenerating retina. Therefore, strategies to enhance the anti-inflammatory and neuroprotective cargo of sEVs have become a focal point of translational research.

In this context, recent investigations have focused on preconditioning MSCs with pro-inflammatory stimuli to potentiate the therapeutic payload of their secreted vesicles. Preconditioning with tumor necrosis factor-alpha (TNF-α), a pivotal cytokine in inflammation, has been shown to remodel the vesicle cargo, specifically enriching anti-inflammatory microRNAs (miRNAs) which are key post-transcriptional regulators of gene expression. A groundbreaking study has now elucidated the therapeutic dynamics of sEVs derived from TNF-α-preconditioned mesenchymal stem cells, hereafter termed T-sEVs, in the setting of inflammatory retinal injury.

Detailed molecular profiling revealed that TNF-α priming alters the miRNA content of sEVs in a way that skews the regulatory milieu toward anti-inflammatory pathways. Among the enriched miRNAs, miR-146a-5p stands out as a crucial modulator, renowned for its capacity to dampen inflammatory signaling cascades such as those mediated by toll-like receptors and nuclear factor-kappa B (NF-κB). The enriched presence of such miRNAs endows T-sEVs with a significantly enhanced ability to counteract macrophage-mediated inflammation, a key contributor to retinal degeneration.

Functional assays demonstrated that T-sEVs are efficiently internalized by macrophages, the immune cells instrumental in orchestrating retinal inflammation. Once internalized, T-sEVs exert a pronounced inhibitory effect on the polarization of macrophages towards the pro-inflammatory M1 phenotype. This polarization suppression is accompanied by a reduction in the expression of hallmark pro-inflammatory genes such as Cd86, Il1r1, and Nos2, as well as a decrease in the secretion of inflammatory cytokines. This dual effect not only curtails the inflammatory cascade but may also preserve the retinal microenvironment conducive to neural survival.

The mechanistic underpinnings of these interactions were elucidated through integrated analyses combining vesicle miRNA profiling with recipient macrophage transcriptomics. These studies demonstrated direct targeting of inflammatory regulators, leading to modulation of critical signaling pathways including cytokine signaling and mitogen-activated protein kinase (MAPK) activity. This multilayered regulatory network highlights how T-sEVs reprogram immune cell behavior at the molecular level, offering a comprehensive attenuation of pathological inflammation.

To translate these findings into an in vivo context, the efficacy of T-sEVs was evaluated using a murine model of retinal degeneration induced by sodium iodate (NaIO3). Intravitreal administration of T-sEVs markedly preserved retinal function and anatomical integrity compared to controls. Notably, treated retinas exhibited reduced macrophage infiltration—a hallmark of diminished inflammation—and preservation of key retinal layers, as assessed by electrophysiological and histological analyses. These effects underscore the therapeutic potential of T-sEVs in mitigating inflammatory insult and neuronal loss in retinal degenerative conditions.

Equally important, thorough evaluations confirmed the safety profile of T-sEVs following local intravitreal administration. Both local ocular examinations and systemic toxicological assessments revealed no adverse effects, affirming that applying T-sEV-based therapy does not provoke harmful immune reactions or organ toxicity. This safety assurance is paramount for advancing such cell-free therapies toward clinical application.

Taken together, the evidence strongly supports the concept that inflammatory preconditioning of MSCs with TNF-α significantly enhances the therapeutic competence of their extracellular vesicles. T-sEVs emerge as potent immunomodulatory agents capable of rebalancing retinal immune homeostasis, suppressing detrimental macrophage activation, and protecting neural tissue integrity. This innovative approach offers a compelling alternative to cell-based therapies, circumventing challenges such as cell engraftment and potential tumorigenicity.

The implications of these findings extend beyond retinal disease, providing a paradigm for harnessing cytokine-primed extracellular vesicles for managing a spectrum of inflammatory disorders. By fine-tuning the bioactive cargo of sEVs through targeted preconditioning, it becomes possible to tailor their therapeutic properties to specific pathological contexts, maximizing efficacy while minimizing risks.

As this research enters the translational pipeline, several avenues warrant exploration, including optimization of dosing regimens, long-term efficacy studies, and evaluation in larger animal models. Furthermore, elucidating the interplay between sEVs and resident retinal cell types such as retinal pigment epithelial cells and Müller glia may unlock additional mechanisms of neuroprotection and regeneration.

In summary, T-sEVs derived from TNF-α-preconditioned mesenchymal stem cells present an innovative and promising cell-free therapeutic modality for inflammatory retinal degeneration. Their enriched anti-inflammatory miRNA cargo, effective modulation of macrophage polarization, and neuroprotective activity converge to address the complex pathology of diseases like dry AMD. Continued research and clinical development hold the promise of introducing a novel class of extracellular vesicle-based therapeutics that could revolutionize the management of debilitating retinal disorders that currently lack effective treatments.

Subject of Research: Not applicable

Article Title: Extracellular vesicles derived from TNF-α-preconditioned mesenchymal stem cells mitigate inflammatory retinal injury

News Publication Date: 17-Mar-2026

Web References: http://dx.doi.org/10.20517/evcna.2025.159

Image Credits: HIGHER EDUCATION PRESS

Keywords: Inflammation, Retinal degeneration, Mesenchymal stem cells, Small extracellular vesicles, TNF-α preconditioning, miR-146a-5p, Macrophage polarization, Cytokine signaling, MAPK pathway, Neuroprotection, Dry age-related macular degeneration, Cell-free therapy

Diabetic retinopathy remains one of the leading causes of vision loss worldwide, entailing complex pathological changes in retinal cell populations. Müller cells, essential for maintaining retinal homeostasis and providing metabolic and structural support, become critically impaired under diabetic conditions, exacerbating neuronal degeneration and blood-retina barrier breakdown. Conventional therapies largely address symptoms but fail to prevent or reverse Müller cell dysfunction at a molecular level, highlighting an urgent need for innovative approaches targeting intracellular repair mechanisms.

The research team conducted an in-depth analysis of the bioactive cargo within MSC-derived sEVs, which have emerged as promising therapeutic agents due to their ability to transfer proteins, lipids, and nucleic acids between cells. They focused on miR-125a-5p, a microRNA previously implicated in various cellular protective processes but never before linked directly to retinal glial cell survival in the context of diabetes. Through rigorous assays, it was demonstrated that these vesicles efficiently deliver miR-125a-5p into Müller cells, exerting a modulatory effect on mitophagy.

Mitophagy, the selective degradation of damaged or dysfunctional mitochondria, serves as a crucial quality control system maintaining cellular energy balance and preventing oxidative stress. In diabetic retinopathy, excessive mitochondrial damage overwhelms this system, contributing to cellular demise. By refining mitophagy regulation via miR-125a-5p, the MSC-derived sEVs restore mitochondrial function, curbing apoptotic cascades and promoting Müller cell resilience amid hyperglycemic conditions.

Central to this protective effect is the interaction of miR-125a-5p with the protein tyrosine phosphatase 1B (PTP1B) pathway. PTP1B, a well-characterized negative regulator of insulin signaling, is hyperactivated in diabetes and implicated in promoting inflammation and cellular stress. The study revealed that miR-125a-5p downregulates PTP1B expression in Müller cells, disentangling harmful signaling networks that otherwise impair mitophagic processes. This strategic modulation reinstates mitophagy balance, fostering mitochondrial health and cellular survival.

The experimental design integrated both in vitro and in vivo models. Müller cells subjected to high glucose stress exhibited marked improvements in mitochondrial morphology and function following treatment with miR-125a-5p-enriched MSC-sEVs. These findings were corroborated in diabetic rodent models where intraocular injections of the vesicles preserved retinal architecture and visual function, underscoring translational potential. Importantly, no significant immune reaction or adverse effects were observed, pointing toward a safe therapeutic profile.

From a molecular standpoint, the study employed advanced sequencing technologies to map the miRNA profile of the MSC-derived vesicles, confirming miR-125a-5p as a critical effector molecule. Mechanistic experiments using miRNA inhibitors and PTP1B knockdown further validated the causal relationship between miR-125a-5p delivery, PTP1B suppression, and enhanced mitophagy flux. Together, these experiments establish a robust framework explaining how extracellular vesicle-mediated intercellular communication reprograms retinal cell metabolism under pathological stress.

This investigation stands at the intersection of stem cell therapy, RNA biology, and mitochondrial quality control, forging new pathways toward retinal neuroprotection. The emphasis on extracellular vesicles leverages their innate capacity for targeted molecular cargo delivery, circumventing challenges associated with direct gene therapy or systemic drug administration. By harnessing the intrinsic reparative capabilities of MSCs through their secreted vesicles, this research ushers in a paradigm shift catering to regenerative medicine.

Clinically, the therapeutic implications are profound. Diabetic retinopathy affects millions, and pharmacological options remain limited primarily to late-stage interventions such as laser therapy and anti-VEGF agents that do not restore cellular function per se. A miRNA-based approach using MSC-derived sEVs offers a minimally invasive strategy to shield Müller cells, potentially halting or reversing retinal degeneration earlier in disease progression. Moreover, targeted modulation of mitophagy through molecular signaling pathways like PTP1B may be applicable to other neurodegenerative and metabolic disorders characterized by mitochondrial dysfunction.

The significance of such a finding extends beyond ophthalmology. Mitophagy dysregulation is a hallmark in numerous chronic conditions, and microRNA-mediated control mechanisms continue to unravel as versatile modulators of cell fate. Understanding how MSC-derived vesicles shuttle specific miRNAs to influence intracellular pathways opens new horizons for harnessing endogenous repair systems in diverse tissues. This study exemplifies the convergence of exosome biology and RNA therapeutics with functional outcomes in cellular metabolism and survival.

Future research directions highlighted in the paper include optimizing vesicle production for large-scale clinical use, deciphering long-term effects of repeated treatments, and exploring combinatory therapies that integrate mitophagy modulation with other protective strategies. Additionally, a deeper dive into the molecular crosstalk between miR-125a-5p and other signaling networks could refine therapeutic specificity, reducing off-target risks. Investigations into the pharmacokinetics and biodistribution of MSC-sEVs remain pivotal to translating these preclinical insights into human applications.

Fundamentally, this study raises critical questions about the plasticity of retinal glial cells and their capacity for self-repair when provided with molecular tools through extracellular vesicle platforms. It illustrates that precise microRNA cargo engineering within stem cell-derived vesicles can recalibrate disrupted cellular homeostasis, offering a blueprint for future interventions in chronic degenerative diseases. By focusing on mitophagy and PTP1B signaling, the researchers have pinpointed a therapeutically actionable axis reflective of underlying pathological mechanisms.

In summary, the innovative approach of employing miR-125a-5p-loaded MSC-derived small extracellular vesicles marks a significant advance in combating diabetic retinopathy-related retinal damage. This therapeutic avenue harnesses biologically sophisticated vesicle-mediated communication to restore mitochondrial integrity and preserve Müller cell function. As the burden of diabetes-related vision impairment continues to grow globally, such molecularly targeted, cell-free therapies hold promise for reshaping clinical management toward more effective, regenerative paradigms.

Subject of Research: The study focuses on the role of miR-125a-5p in MSC-derived small extracellular vesicles in mitigating Müller cell injury in diabetic retinopathy by regulating mitophagy via the PTP1B pathway.

Article Title: MiR-125a-5p in MSC-derived small extracellular vesicles alleviates Müller cells injury in diabetic retinopathy by modulating mitophagy via PTP1B pathway.

Article References: Liu, C., Xiang, J., Chen, Y. et al. MiR-125a-5p in MSC-derived small extracellular vesicles alleviates Müller cells injury in diabetic retinopathy by modulating mitophagy via PTP1B pathway. Cell Death Discov. 11, 226 (2025). https://doi.org/10.1038/s41420-025-02439-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02439-3